x.com· @ · X·· 2026-04-22Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
daraxonrasib ± GnP · mono ORR 47%; +GnP ORR 55%, DCR 90%
Body
7/ Spearheaded by @LisaCSchweizer (@OmicVision) and @jiminmin_v from @Aiims1742 group (@Perlmutter_CC), with Michael Hollingsworth and Paul Grandgenett (@unmc), and the full OmicVision crew. A true team effort. None of this would have happened without an amazing team.
#AACR26 #PancreaticCancer #DeepVisualProteomics #DVP
Heat 6 · 5 likes · 0 replies · 1 repost
Source: x.com · x.com